NASDAQ$DCTH
Delcath Systems Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Delcath reported a net loss of $4.3 million and product revenue of $262 thousand.
Delcath Systems, Inc. announced financial results for the quarter ended June 30, 2020. The company completed a $22 million public offering and uplisted to the NASDAQ Capital Market. Product revenue was $262 thousand, and the net loss was $4.3 million.
- Completed a $22 million public offering to fund the Phase 3 registration trial of Melphalan/HDS in liver-dominant metastatic ocular melanoma (mOM) and refiling of an NDA with the FDA.
- Uplisted to the NASDAQ Capital Market.
- Initiated pre-commercialization work for Melphalan/HDS in mOM.
- Management is focused on delivering top-line results for the Phase 3 FOCUS trial by year-end 2020/early 2021.
Headline financials
Revenue & EPS history
Delcath · Revenue · Quarterly
$98K
Forward guidance
Delcath expects top-line results from the Phase 3 FOCUS trial by year-end 2020/early 2021 and plans to submit a New Drug Application (NDA) by mid-2021. They also intend to initiate additional clinical studies for Melphalan/HDS in liver-dominant orphan cancers.
Tailwinds
- Completion of Phase 3 FOCUS trial in metastatic ocular melanoma by year-end 2020/early 2021.
- Potential FDA approval in the second half of 2021 for Melphalan/HDS as a treatment for mOM patients.
- Initiation of additional studies in one or more liver-dominant metastatic indications.
- Sufficient cash runway through multiple value inflection points.
- The company expects to initiate at least one additional clinical development program of Melphalan/HDS in coming quarters.
Headwinds
- Covid-19 has affected clinical trials, including the Phase 3 FOCUS registration trial.
- Restrictions to clinical sites for data entry and monitoring during the quarter.
- Net loss of $4.3 million for the quarter ended June 30, 2020.
- Reliance on cash resources and anticipated milestone payments to fund operating activities into mid-year 2021.
- The company used $7.9 million of cash in operating activities during the three months ended June 30, 2020.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
-2.1%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+7.7%
Avg return
30 days after
28%
9 / 32 earnings
Positive
+37.5%
Q2 2019
Best reaction
-26.4%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.3% | +0.6% | -5.3% | |
| Q4 2025 | -11.7% | -15.8% | -12.1% | |
| Q3 2025 | -4.7% | -9.2% | +5.3% | |
| Q1 2025 | +23.6% | +31.7% | +41.1% | |
| Q4 2024 | -1.6% | -12.1% | -18.0% | |
| Q3 2024 | -9.0% | -14.0% | +8.5% | |
| Q2 2024 | -2.6% | -4.2% | +33.7% | |
| Q1 2024 | +33.1% | +40.2% | +37.4% | |
| Q4 2023 | +9.2% | +2.4% | +12.9% | |
| Q3 2023 | -23.7% | -16.9% | +10.0% | |
| Q2 2023 | -20.6% | -23.3% | +18.2% | |
| Q1 2023 | +0.2% | +7.8% | +14.9% | |
| Q4 2022 | +22.3% | +18.8% | +17.6% | |
| Q3 2022 | -6.7% | +0.0% | +11.3% | |
| Q2 2022 | -2.3% | +10.2% | -5.4% | |
| Q1 2022 | -11.9% | -16.7% | -28.1% | |
| Q4 2021 | +1.3% | +2.8% | +0.0% | |
| Q3 2021 | -1.8% | -5.0% | -28.1% | |
| Q2 2021 | -11.8% | -13.5% | +1.1% | |
| Q1 2021 | -7.0% | -0.6% | +9.8% | |
| Q4 2020 | -24.8% | -7.2% | -31.8% | |
| Q3 2020 | +0.6% | +3.6% | +36.7% | |
| Q2 2020 | -2.6% | -4.6% | -9.3% | |
| Q1 2020 | -5.2% | -5.2% | +0.5% | |
| Q4 2019 | +0.0% | +13.8% | +55.7% | |
| Q3 2019 | -4.3% | -4.3% | -15.2% | |
| Q2 2019 | +37.5% | +27.5% | +26.2% | |
| Q1 2019 | -11.2% | +0.0% | +22.5% | |
| Q4 2018 | -6.5% | -8.9% | -35.5% | |
| Q3 2018 | -26.4% | -0.3% | -5.6% | |
| Q2 2018 | +0.0% | +19.0% | +78.8% | |
| Q1 2018 | +2.4% | +0.3% | -0.6% | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro